NCT06104826View on ClinicalTrials.gov

Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab

Not yet recruitingOBSERVATIONAL

Enrollment

50

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Hemophilia A

Interventions

DRUG

Emicizumab

Emicizumab in Hemophilia A

Trial Locations (1)

07112

Newark Beth Israel Medical Center, Newark

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Newark Beth Israel Medical Center

OTHER